The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

Background: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction. Treatment commonly includes disease-modifying antirheumatic drugs (DMARDs), such as met...

Full description

Bibliographic Details
Main Authors: Jonathan Shepherd, Keith Cooper, Petra Harris, Joanna Picot, Micah Rose
Format: Article
Language:English
Published: NIHR Journals Library 2016-04-01
Series:Health Technology Assessment
Subjects:
juvenile idiopathic arthritis
polyarticular-course juvenile idiopathic arthritis
oligoarthritis
disease-modifying antirheumatic drugs
antitnf therapy
systematic review
economic evaluation
Online Access:https://doi.org/10.3310/hta20340

Internet

https://doi.org/10.3310/hta20340

Similar Items